MedCity News
SEPTEMBER 2, 2024
Many healthcare providers saw their revenues and operating margins grow in July, despite the fact that both labor and non-labor expenses continue to grow, according to new data. The post Hospitals’ Finances Are Getting Steadier, But Cost Pressures May Ruin That Soon appeared first on MedCity News.
Pharmaceutical Technology
SEPTEMBER 2, 2024
The US regulatory agency has also approved updated versions of Covid-19 vaccines from Moderna and Pfizer / BioNTech’s in the past two weeks.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
SEPTEMBER 2, 2024
Despite the evidence of their positive impact, pharmacists today lack the ability to reliably bill for clinical services as healthcare providers. It is important that payers provision pharmacists, include them in networks, and enable reimbursement through traditional billing models. The post Pharmacists Embrace Provider Status in Healthcare, but Hurdles Remain appeared first on MedCity News.
Pharmaceutical Technology
SEPTEMBER 2, 2024
GLP-1RAs’ reduce CV risk, including reducing all-cause mortality and risk of MI, promoting weight loss and enhancing blood pressure control.
MedCity News
SEPTEMBER 2, 2024
A federal judge recently blocked the FTC’s ban on noncompetes. The decision has important implications for healthcare. The post A Federal Judge Struck Down FTC’s Ban on Noncompetes. What Does This Mean for Healthcare? appeared first on MedCity News.
pharmaphorum
SEPTEMBER 2, 2024
Sanofi eyes filings for multiple sclerosis therapy tolebrutinib, although two of three phase 3 trials miss their primary endpoints
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
SEPTEMBER 2, 2024
Aptose Biosciences has secured a loan of $10m through a facility agreement with Hanmi Pharmaceutical to develop tuspetinib.
pharmaphorum
SEPTEMBER 2, 2024
iRhythm's Zio XT wearable heart monitor raises AFib diagnoses by 52%, but doesn't reduce stroke hospitalisations in GUARD-AF trial.
MedCity News
SEPTEMBER 2, 2024
As RNA biology and RNA therapeutics emerge in the mainstream of pharma, RNA foundation models offer massive potential for revolutionizing R&D. The post RNA Foundation Models to Improve Pharma R&D Productivity appeared first on MedCity News.
pharmaphorum
SEPTEMBER 2, 2024
UNICEF has issued an emergency tender to secure mpox vaccines for countries dealing with the brunt of the current outbreak
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
SEPTEMBER 2, 2024
Nxera will receive $35m from Neurocrine triggered by the successful completion of the Phase II trial of NBI-568 in schizophrenia.
pharmaphorum
SEPTEMBER 2, 2024
Biotech industry body BIA calls for new UK Chancellor Rachel Reeves to take sector-specific approach to R&D tax credits to tackle widespread fraud and abuse of the system.
Pharmaceutical Technology
SEPTEMBER 2, 2024
PHC Corporation has introduced a prototype of LiCellGrow, a cell expansion system designed to manufacture cell and gene therapy products.
Pharmaceutical Commerce
SEPTEMBER 2, 2024
The 8,000 square-foot facility—located within the wholesaler’s Le Vergne distribution center— is expected to help tackle cell and gene therapy logistical challenges.
PharmExec
SEPTEMBER 2, 2024
The insurance company is offering the guidance in response to continued popularity of the drugs which are commonly used for weight-loss management.
PharmaTech
SEPTEMBER 2, 2024
Updating your audits and inspections program ensures inspection preparedness, says Siegfried Schmitt, vice president, Technical at Parexel.
PharmExec
SEPTEMBER 2, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
SEPTEMBER 2, 2024
New insights on the PACMAN-AMI trial for patients with acute myocardial infarction are presented at the ESC Congress, among other updates.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmacy Times
SEPTEMBER 2, 2024
Cases have been detected in 33 US states so far this year, and the virus has recently hospitalized the former Chief Medical Advisor to the President of the US Anthony Fauci.
Pharmaceutical Technology
SEPTEMBER 2, 2024
The pharmaceutical industry is continuously evolving, driven by the imperative to develop more effective and personalized treatments.
Pharmacy Times
SEPTEMBER 2, 2024
For those with unexplained pregnancy loss, these results could prove promising improvements to birth outcomes.
Pharmaceutical Technology
SEPTEMBER 2, 2024
Jacobio Pharma has out-licensed the China rights of its assets, glecirasib and JAB-3312, to Shanghai Allist Pharmaceuticals.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmacy Times
SEPTEMBER 2, 2024
Robert Walker discusses the updated COVID-19 vaccines targeting the new JN.1 lineage of the virus and the challenges of addressing vaccine hesitancy to protect individuals and communities.
Pharmaceutical Technology
SEPTEMBER 2, 2024
A single-pill combination could present a better option for hypertension patients, said researchers at the ESC congress.
Pharmacy Times
SEPTEMBER 2, 2024
High-cost novel therapies challenge payers and patients, while biosimilars help balance affordability.
Pharmaceutical Technology
SEPTEMBER 2, 2024
Johnson & Johnson has selected Onco360 as a pharmacy partner for the distribution of LAZCLUZE (lazertinib).
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
European Pharmaceutical Review
SEPTEMBER 2, 2024
Three anti-hypertensive drugs combined in low doses into a single pill has been shown to be superior to standard care for lowering blood pressure in patients with uncontrolled hypertension. The oral treatment GMRx2 is biopharma George Medicines’ lead drug candidate. The once-daily, three-in-one pill contains telmisartan, amlodipine and indapamide at a quarter, half or standard doses.
Expert insights. Personalized for you.
106 
Let's personalize your content